Jounce's Newly Restructured Deal Is Still Bullish For Its Long-Term Prospects [Seeking Alpha]
Jounce Therapeutics, Inc. (JNCE)
Last jounce therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.jouncetx.com
Company Research
Source: Seeking Alpha
Jounce's Newly Restructured Deal Is Still Bullish For Its Long-Term Prospects Summary Jounce Therapeutics established updated deal with Celgene with the potential to earn up to $530 million in payments based on JTX-8064. Vopratelimab plus ipilimumab has seen positive synergistic effects in the phase 1/2 ICONIC study in solid tumor patients. Based on positive data from the phase 1/2 ICONIC study, Jounce moved forward to initiate its phase 2 EMERGE study exploring vopratelimab plus ipilimumab in NSCLC or urothelial cancer. Jounce Therapeutics had $173.2 million in cash, cash equivalents and investments as of March 31, 2019; Updated deal with Celgene brings in $50 million which means no risk of near-term dilution. JNCE established an updated deal with its partner CELG Updated Deal Is Still Solid The newly updated deal allows Celgene to gain access to a macrophage drug known as JTX-8064. This deal involves Jounce receiving an upfront payment of $50 million, with the potential to earn $480
Show less
Read more
Impact Snapshot
Event Time:
JNCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNCE alerts
High impacting Jounce Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics